Krystal Biotech, Inc. (KRYS) Guidance & Earnings Results
On 2026-01-12 Krystal Biotech, Inc. raised guidance: "VYJUVEK full year 2025 revenue $388-389M; 2026 expense guidance…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
KRYSKrystal Biotech, Inc.Follow KRYS — free
—
Price chart with a free account
- Market cap
- 9.2B
- P/E TTM
- 39.0
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 12 Jan 26 | Raised | VYJUVEK full year 2025 revenue $388-389M; 2026 expense guidance $175-195M |
Krystal Biotech, Inc. — questions
- What guidance did Krystal Biotech, Inc. give?
- On 2026-01-12: "VYJUVEK full year 2025 revenue $388-389M; 2026 expense guidance $175-195M"
- When does Krystal Biotech, Inc. report earnings?
- Krystal Biotech, Inc.'s next earnings report is expected on 2026-11-09.
Every figure on this page comes from Krystal Biotech, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.